SCHEMBL15534015

SCHEMBL15534015

CC(C)N(Cc1cccc(-c2nccs2)c1)C(=O)Nc1ccc2c(c1)CCC2

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 5/20 0.67
KCNB1 Q14721 9/20 0.48
KCNA5 P22460 2/20 0.48
KCNH2 Q12809 1/20 0.48
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
ROCK2 O75116 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
UBE2M P61081 1/20 0.41
DCUN1D1 Q96GG9 1/20 0.41
CASR P41180 1/20 0.41
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15533533 0.85 NTRK1 (0.75) NTRK1KCNB1KCNA5KCNH2ROCK2
SCHEMBL16714194 0.85 NTRK1 (0.76) NTRK1KCNB1KCNA5KCNH2ROCK2
SCHEMBL15532866 0.84 NTRK1 (0.70) NTRK1KCNB1KCNA5KCNH2ROCK2
SCHEMBL16714195 0.84 NTRK1 (0.72) NTRK1KCNB1KCNA5KCNH2ROCK2
SCHEMBL15533086 0.84 NTRK1 (0.74) NTRK1KCNB1KCNA5KCNH2ROCK2
SCHEMBL15533140 0.84 NTRK1 (0.77) NTRK1KCNB1KCNA5KCNH2ROCK2
SCHEMBL15534547 0.84 NTRK1 (0.74) NTRK1KCNB1KCNA5KCNH2ROCK2
SCHEMBL15533539 0.84 NTRK1 (0.72) NTRK1KCNB1KCNA5KCNH2NPC1
SCHEMBL15533241 0.84 NTRK1 (0.69) NTRK1KCNB1KCNA5KCNH2RAB9A
SCHEMBL15533793 0.84 NTRK1 (0.71) NTRK1KCNB1KCNA5KCNH2ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150141428-A1 TrkA Kinase Inhibitors, Compositions and Methods Thereof MERCK SHARP & DOHME CORP. (US) 2015-05-21 US claimed
EP-2858501-A1 TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF Merck Sharp & Dohme Corp. (US) 2015-04-15 EP claimed
WO-2013176970-A1 TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF MERCK SHARP & DOHME CORP. (US) 2013-11-28 WO claimed
US-9181261-B2 TrkA kinase inhibitors, compositions and methods thereof MERCK SHARP & DOHME CORP. (US) 2015-11-10 US disclosed
US-9181261-B2 TrkA kinase inhibitors, compositions and methods thereof MERCK SHARP & DOHME CORP. (US) 2015-11-10 US disclosed
US-9181261-B2 TrkA kinase inhibitors, compositions and methods thereof MERCK SHARP & DOHME CORP. (US) 2015-11-10 US disclosed
US-20150141428-A1 TrkA Kinase Inhibitors, Compositions and Methods Thereof MERCK SHARP & DOHME CORP. (US) 2015-05-21 US disclosed
US-20150141428-A1 TrkA Kinase Inhibitors, Compositions and Methods Thereof MERCK SHARP & DOHME CORP. (US) 2015-05-21 US disclosed
US-20150141428-A1 TrkA Kinase Inhibitors, Compositions and Methods Thereof MERCK SHARP & DOHME CORP. (US) 2015-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150141428-A1 TrkA Kinase Inhibitors, Compositions and Methods Thereof NGF, NGFR, NTRK1 NTRK1 3/4885KCNB1 1686/4885KCNA5 3098/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.